Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have received an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $20.00.

ENTA has been the subject of several recent analyst reports. Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. JPMorgan Chase & Co. reduced their target price on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 6th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 price target on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 9th.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $11.26 on Wednesday. The company has a market capitalization of $238.59 million, a P/E ratio of -2.07 and a beta of 0.56. Enanta Pharmaceuticals has a fifty-two week low of $8.08 and a fifty-two week high of $17.80. The stock has a 50 day moving average price of $11.65 and a two-hundred day moving average price of $12.68.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) EPS for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.36. The company had revenue of $17.97 million during the quarter, compared to analyst estimates of $17.44 million. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The firm’s revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.27) EPS. As a group, equities analysts predict that Enanta Pharmaceuticals will post -5.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ENTA. Vanguard Group Inc. increased its stake in shares of Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after acquiring an additional 134,292 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of Enanta Pharmaceuticals by 3.5% during the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after purchasing an additional 70,000 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Enanta Pharmaceuticals by 65.8% during the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after purchasing an additional 18,003 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 1.3% during the first quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock valued at $14,906,000 after purchasing an additional 10,952 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Enanta Pharmaceuticals in the 1st quarter worth approximately $191,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.